DOCSLIB.ORG

Pyrexia of Unknown Origin. Presenting Sign of Hypothalamic Hypopituitarism R

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pyrexia of Unknown Origin. Presenting Sign of Hypothalamic Hypopituitarism R Postgrad Med J: first published as 10.1136/pgmj.57.667.310 on 1 May 1981. Downloaded from Postgraduate Medical Journal (May 1981) 57, 310-313 Pyrexia of unknown origin. Presenting sign of hypothalamic hypopituitarism R. MARILUS* A. BARKAN* M.D. M.D. S. LEIBAt R. ARIE* M.D. M.D. I. BLUM* M.D. *Department of Internal Medicine 'B' and tDepartment ofEndocrinology, Beilinson Medical Center, Petah Tiqva, The Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel Summary least 10 such admissions because offever of unknown A 62-year-old man was admitted to hospital 10 times origin had been recorded. During this period, he over 12 years because of pyrexia of unknown origin. was extensively investigated for possible infectious, Hypothalamic hypopituitarism was diagnosed by neoplastic, inflammatory and collagen diseases, but dynamic tests including clomiphene, LRH, TRH and the various tests failed to reveal the cause of theby copyright. chlorpromazine stimulation. Lack of ACTH was fever. demonstrated by long and short tetracosactrin tests. A detailed past history of the patient was non- The aetiology of the disorder was believed to be contributory. However, further questioning at a previous encephalitis. later period of his admission revealed interesting Following substitution therapy with adrenal and pertinent facts. Twelve years before the present gonadal steroids there were no further episodes of admission his body hair and sex activity had been fever. normal. At that time he had an acute febrile illness with severe headache which lasted for about one Introduction week. He was not admitted to hospital and did not http://pmj.bmj.com/ Pyrexia of unknown origin (PUO) may present receive any specific therapy. some of the most challenging problems that the Following this illness his hair started to fall and clinician is called upon to solve. Infectious, inflam- he noticed a decline in his sexual activity. In the matory, neoplastic and collagen diseases are the following years there were recurrent bouts of fever, most frequent final diagnoses in these cases (Jacoby sometimes accompanied by episodes of diarrhoea and Swartz, 1973). Fever may be the presenting and vomiting, with a picture of dehydration and symptom of several, less frequent entities which, if lowering of BP which were twice diagnosed as not specifically suspected, may be overlooked. septic and cardiogenic shock. During these episodes on September 30, 2021 by guest. Protected The authors present the case of a 62-year-old steroids were administered and the patient recovered. man, whose frequent bouts of fever were undiag- Concomitantly a psychiatric disorder developed with nosed for 12 years. The cause of his disease was auditory hallucinations and paranoidal thinking. finally proved to be hypothalamic hypopituitarism. On examination the patient appeared well nourished, his BP was 100/70 mmHg and his pulse Case report rate was regular at 80/min. There was no hair on his A 62-year-old man was admitted to the Depart- chest or axillae, his pubic hair had a feminine con- ment of Internal Medicine 'B' because of fever of up figuration, and his testes were hypotrophic (4ml to 38.5°C of one day's duration. There were no vol). No other abnormal physical findings were complaints concerning the urinary, respiratory or detected. gastrointestinal tracts. The body temperature re- A confrontation test revealed a bitemporal turned to normal one day after admission, without hemianopia. Routine laboratory tests which in- any specific therapy and remained so throughout his cluded total blood count, blood urea nitrogen, stay in hospital. creatinine and electrolytes were all in the normal In the 12 years before the present admission at range. 0032-5473/81/0500-0310 $02.00 © 1981 The Fellowship of Postgraduate Medicine Postgrad Med J: first published as 10.1136/pgmj.57.667.310 on 1 May 1981. Downloaded from Case reports 31i TABLE 1. Adrenal function. Plasma cortisol and urine 17-ketosteroid (17-KS), 17-hydroxycorticoid (17-OH), and 1 1-oxy-17-KS (11-OH) responses to tetracosactrin Base-line Short tetracosactrin test Long tetracosactrin test Plasma ACTH (pg/ml) 0 Cortisol (nmol/I) 27-6 41-4* Urine 17-KS mg/24/hr 0-6 3-0 0-4 17-OH mg/24/hr 1-3 3-5 18-5 11-OH [Lg/24/hr 9 130 *After 120 and 240 min or tetracosactrin infusion. Since the physical findings were suggestive of lack of prolactin-inhibiting factor (PIF) reaching adrenal and gonadal insufficiency, the functions of the pituitary gland, due to either a hypothalamic these glands were investigated basally and upon lesion or a hypophiseal stalk section (Thorner, 1977). stimulation. Administration of TRH is believed to stimulate Tertiary adrenal, gonodal and mild thyroid dys- directly the pituitary secretion of prolactin (Jacob function and hyperprolactinaemia were diagnosed et al., 1971). There was increased response to TRH (Tables 1, 2, 3). Basal 24-hr urinary steroid excretion, (Table 3), possibly as an expression of increased basal plasma cortisol and plasma ACTH levels were receptor sensitivity due to lack of PIF. Dopamine is all extremely low (Table 1), suggesting the presence believed to be a PIF (Shaar and Clemens, 1974; of adrenal insufficiency. A tetracosactrin (Synacthen) Enyalbert, Pria and Korden, 1977). Administration test (0-25 mg i.v. over 4 hr) revealed no increase in of chlorpromazine, known to be a hypothalamic plasma and urine steroid levels, suggesting either primary adrenal insufficiency or secondary adrenal TABLE 2. Hypothalamic-pituitary-gonadal axis function. atrophy resulting from long-standing absence of Follicle stimulating hormone (FSH) and luteinizing hormone by copyright. trophic action of endogenic ACTH. A long tetraco- (LH) responses to LH-releasing hormone (LHRH) and sactrin test (0-25 mg i.v. over 4 hr for 3 consecutive clomiphene days) revealed an appropriate rise of urine excretion LHRH test (100 jLg i.v.) of corticosteroids, suggesting the presence of Time Plasma FSH Plasma LH adrenal insufficiency of pituitary or hypothalamic (min) (mu./ml) (mu./ml) origin (Liddle, 1974). 0 2-3 2-2 Differentiation between these 2 possibilities is 15 4-1 4-4 generally accomplished by performing insulin 30 4-7 5.9 45 5-0 6-4 http://pmj.bmj.com/ tolerance (ITT) and vasopressin tests (Landon et al., 60 5-1 5-6 1966; Eddy, 1968), but these could not be performed 90 5.4 5-5 because of the presence of electrocardiographic abnormalities indicative of coronary insufficiency. Clomiphene test (200 mg/day for 6 days) Basal plasma levels of testosterone (62 ng/dl) and Time Plasma FSH Plasma LH gonadotrophins (FSH, LH) were low, suggesting the (mu./ml) (mu./ml) presence of gonadal insufficiency of pituitary or Base-line 2-3 2-2 2 4-0 0-4 hypothalamic origin (Table 2). Administration of day on September 30, 2021 by guest. Protected Iuteinizing hormone day 3 2-4 0-5 hormone-releasing (LHRH)(100 day 4 0-5 0-7 ,ig i.v.) gave an appropriate rise of plasma gonado- day 6 0-8 0-7 trophins, suggesting normal pituitary reserve (Morti- mer et al., 1973). Administration of clomiphene, which is believed to be a hypothalamic stimulator of dopaminergic receptor blocker (Streja, Corenblum LHRH secretion (Mortimer et al., 1973), failed to and Ezrim, 1978), failed to produce an adequate produce an adequate rise of gonadotrophin levels rise in plasma prolactin levels. The combination of (Table 2). The combination of a normal LHRH test an increased response of prolactin secretion to TRH and abnormal clomiphene test suggested a hypo- stimulation and a subnormal response to chlorpro- thalamic lesion as the cause of the hypogonadism in mazine suggested a hypothalamic lesion as the cause this patient (Mortimer, 1977). of the hyperprolactinaemia. Basal plasma levels of prolactin (10-23 ng/ml) Normal values of T3, T4, and TSH (6-8 ig/ml and were found to be above normal. 1-7 ,uu./ml) suggested a normal hypothalamic- Hyperprolactinaemia can be the result of one of pituitary thyroidal axis but cannot be taken as final 2 causes: a hypersecreting pituitary adenoma or a proof (Snyder et al., 1974). Administration of TRH, Postgrad Med J: first published as 10.1136/pgmj.57.667.310 on 1 May 1981. Downloaded from 312 Case reports which is believed to stimulate the pituitary to endocrinological deficits of hypothalamic origin, secrete TSH, showed a delayed peak (Table 3), thus hypersomnia and severe mental disturbances were all confirming impairment of TSH secretion of hypo- found in the patient. These findings may be attributed thalamic origin (Faglia et al., 1973). to what has been described in the literature as the diencephalic syndrome (Bower, 1954). Discussion Substitution therapy with 7-5 mg prednisone/day Endocrinological investigation pointed to a hypo- and injections of testosterone enanthate 250 mg/ thalamic lesion as being the cause of the abnormal month was started. During 16 months of follow-up function of the pituitary, concerning the secretion of there were no more episodes of fever, hypersomnia gonadotrophins, prolactin and TSH. Adrenal in- disappeared, and vigour and libido reappeared. sufficiency was proved but the patient's condition This amelioration on substitution therapy suggests made it technically impossible to determine whether that the adrenal and gonadal insufficiencies were the it was hypothalamic or pituitary in origin. cause of the above-mentioned symptoms, and that these were not due to a lesion of the hypothalamic centres of temperature and alertness, thus excluding TABLE 3. Plasma prolactin and TSH responses to TRH and the of The mental chlorpromazine (Baseline: 10-23 ng/ml; TSH=1-7 ,u./ml; diagnosis diencephalic syndrome. T4=6-8 ,ig/ml) disorder was probably the result of the severe cortex atrophy, a sequel of the encephalitis and/or of long- TRH test (200 ,ug i.v.) standing and irreversible adrenal Time Plasma prolactin Plasma TSH insufficiency (min) (Parker, Isaacs and McKerron, 1976).
Load more

Recommended publications
  • Lymphocytic Hypophysitis Successfully Treated with Azathioprine
    1581 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.74.11.1581 on 14 November 2003. Downloaded from SHORT REPORT Lymphocytic hypophysitis successfully treated with azathioprine: first case report A Lecube, G Francisco, D Rodrı´guez, A Ortega, A Codina, C Herna´ndez, R Simo´ ............................................................................................................................... J Neurol Neurosurg Psychiatry 2003;74:1581–1583 is not well established, but corticosteroids have been An aggressive case of lymphocytic hypophysitis is described proposed as first line treatment.10–12 Trans-sphenoidal surgery which was successfully treated with azathioprine after failure should be undertaken in cases associated with progressive of corticosteroids. The patient, aged 53, had frontal head- mass effect, in those in whom radiographic or neurological ache, diplopia, and diabetes insipidus. Cranial magnetic deterioration is observed during treatment with corticoster- resonance imaging (MRI) showed an intrasellar and supra- oids, or when it is impossible to establish the diagnosis of sellar contrast enhancing mass with involvement of the left lymphocytic hypophysitis with sufficient certainty.25 cavernous sinus and an enlarged pituitary stalk. A putative We describe an unusually aggressive case of pseudotumor- diagnosis of lymphocytic hypophysitis was made and ous lymphocytic hypophysitis successfully treated with prednisone was prescribed. Symptoms improved but azathioprine. This treatment was applied empirically because recurred after the dose was reduced. Trans-sphenoidal of the failure of corticosteroids. To the best to our knowledge, surgery was attempted but the suprasellar portion of the this is the first case of lymphocytic hypophysitis in which mass could not be pulled through the pituitary fossa. such treatment has been attempted. The positive response to Histological examination confirmed the diagnosis of lympho- azathioprine suggests that further studies should be done to cytic hypophysitis.
    [Show full text]
  • Hypothalamic-Pituitary Axes
    Hypothalamic-Pituitary Axes Hypothalamic Factors Releasing/Inhibiting Pituitary Anterior Pituitary Hormones Circulating ACTH PRL GH Hormones February 11, 2008 LH FSH TSH Posterior Target Pituitary Gland and Hormones Tissue Effects ADH, oxytocin The GH/IGF-I Axis Growth Hormone Somatostatin GHRH Hypothalamus • Synthesized in the anterior lobe of the pituitary gland in somatotroph cells PITUITARY • ~75% of GH in the pituitary and in circulation is Ghrelin 191 amino acid single chain peptide, 2 intra-molecular disulfide bonds GH Weight; 22kD • Amount of GH secreted: IGF-I Women: 500 µg/m2/day Synthesis IGF- I Men: 350 µg/m2/day LIVER Local IGF-I Synthesis CIRCULATION GH Secretion: Primarily Pulsatile Pattern of GH Secretion Regulation by two hypothalamic in a Healthy Adult hormones 25 Sleep 20 Growth - SMS Hormone 15 Somatostatin Releasing GHRH + GH (µg/L) Hormone Inhibitory of 10 Stimulatory of GH Secretion GH Secretion 05 0 GHRH induces GH Somatostatin: Decreases to allow 0900 2100 0900 synthesis and secretion Clocktime GH secretory in somatotrophs Bursts GH From: “Acromegaly” by Alan G. Harris, M.D. 1 Other Physiological Regulators of GH Secretion Pharmacologic Agents Used to Stimulate GH Secretion Amino Sleep Exercise Stress Acids Fasting Glucose Stimulate hypothalamic GHRH or Inhibit Somatostatin Hypothalamus GHRH SMS Hypoglycemia(Insulin) Pituitary L-dopa Arginine Clonidine GHRH + - SMS Pyridostigmine GH Target Tissues Metabolic & Growth Promoting GH Effects IGF-I Insulin-like growth factor I (IGF-I) Major Determinants of Circulating
    [Show full text]
  • Hyperprolactinaemia Common and Treatable
    cardiology, and 8 Asherson RA, Harris EN, Gharavi AE, Hughes GRV. Systemic lupus erythematosus, anti- haematology, neurology, rheumatology phospholipid antibodies, chorea, and oral contraceptives. Arthritis Rheum 1986;29:1535-6. clinics as well as in obstetrics. 9 Asherson RA, Chan JKH, Harris EN, Gharavi AE, Hughes GRV. Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal. Ann Rheum Dis 1985;44:823-5. Treatment depends on careful anticoagulation, but the 10 Asherson RA, Lanham J, Hull RG, Boev ML, Gharavi AE, Hughes GRV. Renal vein thrombosis in value of steroids, immunosuppressive agents, and plasma systemic lupus erythematosus: association with the "lupus anticoagulant." Clin Exp Rheumatol 1984;2:75-9. exchange is still not clear. In obstetrics, although claims 11 Hughes GRV, Mackworth-Young CG, Harris EN, Gharavi AE. Veno-occlusive disease in systemic BMJ: first published as 10.1136/bmj.297.6650.701 on 17 September 1988. Downloaded from of therapeutic success with various anticoagulation or lupus erythematosus: possible association with anticardiolipin antibodies? Arthritis Rheum 1984;27: 107 1. immunosuppressive regimens increase each year, the data 12 Asherson RA, Mackworth-Young C, Boey ML, et al. Pulmonary hypertension in systemic lupus remain anecdotal and the overall results poor. erythematosus. Br Med] 1983;287:1024-5. 13 Harris EN, Gharavi AE, Asherson RA, Boey ML, Hughes GRV. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol 1984;2:47-5 1. GRAHAM R V HUGHES 14 Asherson RA, Mackay IR, Harris EN. Myocardial infarction in a young male with systemic lupus Consultant Rheumatologist, erythematosus, deep vein thrombosis, and antibodies to phospholipid.
    [Show full text]
  • Clinical Manifestations of Hypothalamic Tumors*
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, Vol. 10, No. 6 Copyright © 1980, Institute for Clinical Science, Inc. Clinical Manifestations of Hypothalamic Tumors* ADOLFO D. GARNICA, M.D., MICHAEL L. NETZLOFF, M.D.,f and A. L. ROSENBLOOM, M.D. Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL 32610 and f Department of Human Development, Michigan State University East Lansing, MI 88823 ABSTRACT The regulatory function of the central nervous system encompasses di­ verse endocrine, metabolic, and behavioral processes. Many of these origi­ nate, are integrated, or are coordinated through hypothalamic pathways or nuclei. Thus, tumors affecting areas projecting to the hypothalamus, tumors of the hypothalamus, and tumors invading or compressing the hypothalamus can produce abnormalities of hypothalamic function. Introduction tary.4,7,31 A secretory function for certain hypothalamic neurons was postulated in Until recently, no endocrine disorder 1928 and subsequently confirmed by the directly attributable to hypothalamic dys­ demonstration of hormone synthesis in function had been recognized, and the the supraoptic and paraventricular nu­ majority of endocrine-metabolic homeo­ clei.28,53 Moreover, observations on the static processes were acknowledged to be effects of environment on the menstrual under the control of the anterior pitui­ cycles of women and the study of repro­ tary.48,49 However, in 1901 Frohlich re­ ductive cycles in animals have shown a ported a patient with a suprasellar tumor, functional connection
    [Show full text]
  • Hypothalamic Hamartoma
    Neurol Med Chir (Tokyo) 45, 221¿231, 2005 Hypothalamic Hamartoma Kazunori ARITA,KaoruKURISU, Yoshihiro KIURA,KojiIIDA*, and Hiroshi OTSUBO* Department of Neurosurgery, Graduate School of Biomedical Science, Hiroshima University, Hiroshima; *Division of Neurology, The Hospital for Sick Children, Toronto, Ontario, Canada Abstract The incidence of hypothalamic hamartomas (HHs) has increased since the introduction of magnetic resonance (MR) imaging. The etiology of this anomaly and the pathogenesis of its peculiar symptoms remain unclear, but recent electrophysiological, neuroimaging, and clinical studies have yielded important data. Categorizing HHs by the degree of hypothalamic involvement has contributed to the accurate prediction of their prognosis and to improved treatment strategies. Rather than undergoing corticectomy, HH patients with medically intractable seizures are now treated with surgery that targets the HH per se, e.g. HH removal, disconnection from the hypothalamus, stereotactic irradiation, and radiofrequency lesioning. Although surgical intervention carries risks, total eradication or disconnec- tion of the lesion leads to cessation or reduction of seizures and improves the cognitive and behavioral status of these patients. Precocious puberty in HH patients is safely controlled by long-acting gonadotropin-releasing hormone agonists. The accumulation of knowledge regarding the pathogenesis of symptoms and the development of safe, effective treatment modalities may lead to earlier interven- tion in young HH patients and prevent
    [Show full text]
  • Oxytocin Therapy in Hypopituitarism: Challenges and Opportunities
    Oxytocin therapy in hypopituitarism: challenges and opportunities Running title: Oxytocin in hypopituitarism Raghav Bhargava*, Katie L Daughters*, D Aled Rees. Schools of Medicine (RB, DAR) and Psychology (KLD), Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff CF24 4HQ, UK *These authors contributed equally to this work. Keywords: Oxytocin; hypopituitarism; central diabetes insipidus; craniopharyngioma Corresponding author: Dr Aled Rees, Neuroscience and Mental Health Research Institute, School of Medicine, Cardiff University CF24 4HQ. Tel: +44 (0)2920 742309; email: [email protected] 1 Summary: Patients with hypopituitarism display impaired quality of life and excess morbidity and mortality, despite apparently optimal pituitary hormone replacement. Oxytocin is a neuropeptide synthesised in the anterior hypothalamus which plays an important role in controlling social and emotional behaviour, body weight and metabolism. Recent studies have suggested that a deficiency of oxytocin may be evident in patients with hypopituitarism and craniopharyngioma, and that this may be associated with deficits in cognitive empathy. Preliminary data hint at potential benefits of oxytocin therapy in improving these deficits and the accompanying metabolic disturbances that are common in these conditions. However, several challenges remain, including an incomplete understanding of the regulation and mechanisms of action of oxytocin, difficulties in accurately measuring oxytocin levels and in establishing a diagnosis of oxytocin deficiency, and a need to determine both the optimal mode of administration for oxytocin therapy and an acceptable safety profile with long-term use. This review considers the data linking oxytocin to the neuropsychological and metabolic disturbances evident in patients with craniopharyngioma and hypopituitarism, and describes the challenges that need to be overcome before replacement therapy can be considered as a therapeutic option in clinical practice.
    [Show full text]
  • Hyperprolactinaemia: a Monster Between the Woman and Her Conception *Seriki A
    Archives of Reproductive Medicine and Sexual Health ISSN: 2639-1791 Volume 1, Issue 2, 2018, PP: 61-67 Hyperprolactinaemia: A Monster Between the Woman and Her Conception *Seriki A. Samuel1, Odetola O. Anthony2 1Department of Human Physiology, College of Medicine, Bingham University, Karu, Nigeria. 2Department of Human Physiology, College Medical Sciences, NnamdiAzikwe University, Awka, Nigeria. [email protected] *Corresponding Author: Seriki A. Samuel, Department of Human Physiology, College of Medicine, Bingham University, Karu, Nigeria. Abstract Hyperprolactinaemia is the presence of abnormally high levels of prolactin in the blood. Normal levels are less than 5000 ml U/L [20ng/mL or µg/L] for women, and less than 450 ml U/L for men.Prolactin is a peptide hormone produced by the adenohypophysis (also called anterior pituitary) that is primarily associated with milk production and plays a vital role in breast development during pregnancy. Hyperprolactinaemia may cause galactorrhea (production and sp; ontaneous ejection of breast milk without pregnancy or childbirth). It also alters/disrupts the normal menstrual cycle in women. In other women, menstruation may cease completely, resulting in infertility. In the man, it could causeerectile dysfunction.The present study is to review the pathophysiology of the abnormality in the woman, and how it relates to the functioning of the hypothalamo- hypophyseal-gonadal system. The article also looks at the effect of hyperprolactinaemia on the fertility of the woman, and attempts to proffer non-surgical remedy to the condition. Keywords: Galactorrhea, adenohypophysis,hypoestrogenism,prolactinoma, amenorrhoea, macroprolactin, microprolactin Introduction It is synthesized by the anterior pituitary lactotrophs and regulated by the hypothalamic–pituitary axis Hyperprolactinaemia, which is a high level of through the release of dopamine, which acts as a prolactin in the blood can be a part of normal prolactin inhibitory factor[2].
    [Show full text]
  • Pediatric Neuro-Ophthalmology
    Pediatric Neuro-Ophthalmology Second Edition Michael C. Brodsky Pediatric Neuro-Ophthalmology Second Edition Michael C. Brodsky, M.D. Professor of Ophthalmology and Neurology Mayo Clinic Rochester, Minnesota USA ISBN 978-0-387-69066-7 e-ISBN 978-0-387-69069-8 DOI 10.1007/978-0-387-69069-8 Springer New York Dordrecht Heidelberg London Library of Congress Control Number: 2010922363 © Springer Science+Business Media, LLC 2010 All rights reserved. This work may not be translated or copied in whole or in part without the written permission of the publisher (Springer Science+Business Media, LLC, 233 Spring Street, New York, NY 10013, USA), except for brief excerpts in connection with reviews or scholarly analysis. Use in connec-tion with any form of information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed is forbidden. The use in this publication of trade names, trademarks, service marks, and similar terms, even if they are not ­identified as such, is not to be taken as an expression of opinion as to whether or not they are subject to proprietary rights. While the advice and information in this book are believed to be true and accurate at the date of going to press, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with re-spect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) To the good angels in my life, past and present, who lifted me on their wings and carried me through the storms.
    [Show full text]
  • NEUROLOGY in TABLE.Pdf
    ZAPORIZHZHIA STATE MEDICAL UNIVERSITY DEPARTMENT OF NEUROLOGY DISEASES NEUROLOGY IN TABLE (General neurology) for practical employments to the students of the IV course of medical faculty Zaporizhzhia, 2015 2 It is approved on meeting of the Central methodical advice Zaporozhye state medical university (the protocol № 6, 20.05.2015) and is recommended for use in scholastic process. Authors: doctor of the medical sciences, professor Kozyolkin O.A. candidate of the medical sciences, assistant professor Vizir I.V. candidate of the medical sciences, assistant professor Sikorskaya M.V. Kozyolkin O. A. Neurology in table (General neurology) : for practical employments to the students of the IV course of medical faculty / O. A. Kozyolkin, I. V. Vizir, M. V. Sikorskaya. – Zaporizhzhia : [ZSMU], 2015. – 94 p. 3 CONTENTS 1. Sensitive function …………………………………………………………………….4 2. Reflex-motor function of the nervous system. Syndromes of movement disorders ……………………………………………………………………………….10 3. The extrapyramidal system and syndromes of its lesion …………………………...21 4. The cerebellum and it’s pathology ………………………………………………….27 5. Pathology of vegetative nervous system ……………………………………………34 6. Cranial nerves and syndromes of its lesion …………………………………………44 7. The brain cortex. Disturbances of higher cerebral function ………………………..65 8. Disturbances of consciousness ……………………………………………………...71 9. Cerebrospinal fluid. Meningealand hypertensive syndromes ………………………75 10. Additional methods in neurology ………………………………………………….82 STUDY DESING PATIENT BY A PHYSICIAN NEUROLOGIST
    [Show full text]
  • Diagnosis and Treatment of Hypopituitarism
    Review Endocrinol Metab 2015;30:443-455 http://dx.doi.org/10.3803/EnM.2015.30.4.443 Article pISSN 2093-596X · eISSN 2093-5978 Diagnosis and Treatment of Hypopituitarism Seong Yeon Kim Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea Hypopituitarism is a chronic endocrine illness that caused by varied etiologies. Clinical manifestations of hypopituitarism are variable, often insidious in onset and dependent on the degree and severity of hormone deficiency. However, it is associated with increased mortality and morbidity. Therefore, early diagnosis and prompt treatment is necessary. Hypopituitarism can be easily diagnosed by measuring basal pituitary and target hormone levels except growth hormone (GH) and adrenocorticotropic hor- mone (ACTH) deficiency. Dynamic stimulation tests are indicated in equivocal basal hormone levels and GH/ACTH deficiency. Knowledge of the use and limitations of these stimulation tests is mandatory for proper interpretation. It is necessary for physi- cians to inform their patients that they may require lifetime treatment. Hormone replacement therapy should be individualized ac- cording to the specific needs of each patient, taking into account possible interactions. Long-term endocrinological follow-up of hypopituitary patients is important to monitor hormonal replacement regimes and avoid under- or overtreatment. Keywords: Hypopituitarism; Adrenocorticotropic hormone deficiency; Thyrotropin deficiency; Gonadotropin deficiency; Growth hormone deficiency; Anti-diuretic hormone deficiency INTRODUCTION mone secretion results in an emergency situation that requires immediate medical attention [2]. The treatment of hypopituita- Hypopituitarism is defined as the total or partial loss of anterior rism typically involves a replacement of the deficient hormone and posterior pituitary gland function that is caused by pituitary but care must be taken because several studies have reported an or hypothalamic disorders [1].
    [Show full text]
  • Animal Models of Central Diabetes Insipidus
    DOI: 10.5772/intechopen.69538 Provisional chapter Chapter 4 Animal Models of Central Diabetes Insipidus: Oxytocin Animaland Low-Sodium Models of Diets Central as ComplementaryDiabetes Insipidus: Treatments Oxytocin and Low-Sodium Diets as Complementary Treatments Antonio Bernal, Javier Mahía and Amadeo Puerto Antonio Bernal, Javier Mahía and Amadeo Puerto Additional information is available at the end of the chapter Additional information is available at the end of the chapter http://dx.doi.org/10.5772/intechopen.69538 Abstract Human central diabetes insipidus (CDI) is a neurobiological syndrome characterized by the presence of hypotonic polyuria, hypernatremia, and polydipsia. CDI can be acquired (aCDI) as the result of brain damage to magnocellular neurosecretory cells or fibers that constitute the hypothalamic-neurohypophyseal system or can be caused by genetic disorders (heredi- tary CDI). aCDI can be experimentally induced by various surgical interventions, including neurohypophysectomy, pituitary stalk compression (PSC), hypophysectomy, and hypotha- lamic mediobasal lesions. CDI has been associated with a deficient production of arginine vasopressin (AVP) (the antidiuretic hormone secreted by magnocellular system), while more recently, aCDI animal studies also suggest the possible involvement of oxytocin (OT) (a natriuretic-promoting hormone secreted by neurosecretory systems) and other factors related to serum fluid concentration. Both humans and animals with aCDI may benefit from the combined administration of AVP and OT and, importantly, from a low-sodium diet. Moreover, increased OT levels are observed in Brattleboro rats (with mutated AVP gene), which may explain the regulatory hydromineral capacity shown by these animals after hydromineral challenges. In short, the symptoms shown by the different CDI animal models suggest the involvement of additional factors besides the absence of AVP, which appear to depend on the particular neurobiological systems affected in each case.
    [Show full text]
  • Diencephalic Syndrome: a Cause of Failure to Thrive and a Model of Partial Growth Hormone Resistance
    Diencephalic Syndrome: A Cause of Failure to Thrive and a Model of Partial Growth Hormone Resistance Amy Fleischman, MD*; Catherine Brue, MD*; Tina Young Poussaint, MD‡; Mark Kieran, MD, PhD§࿣; Scott L. Pomeroy, MD, PhD࿣¶; Liliana Goumnerova, MD࿣#; R. Michael Scott, MD࿣#; and Laurie E. Cohen, MD*࿣ ABSTRACT. Diencephalic syndrome is a rare but po- total of 48 similar cases, including the 12 described tentially lethal cause of failure to thrive in infants and by Russell. Since then, several case studies have been young children. The diencephalic syndrome includes reported with similar symptoms, a few with brain clinical characteristics of severe emaciation, normal lin- tumors located in the posterior fossa.2,3 Nystagmus ear growth, and normal or precocious intellectual devel- and vomiting were also noted in the majority of opment in association with central nervous system tu- reported cases.2–5 In 1976, a review of 72 cases by mors. Our group initially described a series of 9 patients 6 with diencephalic syndrome and found a reduced prev- Burr confirmed the clinical characteristics of dience- alence of emesis, hyperalertness, or hyperactivity com- phalic syndrome. Subsequent literature has consisted pared with previous reports. Also, the tumors were found of multiple case series and case reports of this to be larger, occur at a younger age, and behave more syndrome. aggressively than similarly located tumors without dien- We reviewed the 11 cases of diencephalic syn- cephalic syndrome. We have been able to extend our drome that presented to Children’s Hospital Boston follow-up of the original patients, as well as describe 2 and Dana-Farber Cancer Institute between 1970 and additional cases.
    [Show full text]